Nutriband INC 10-Q quarterly reports

Nutriband Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to a major customer relocating operations, while also noting a reduction in net loss compared to the prior year.

Nutriband Inc. reported a significantly wider net loss for the three and nine months ended October 31, 2025, driven by increased expenses and a preferred stock dividend, despite an increase in cash and working capital.

Nutriband Inc. reported increased revenue and cash for the second quarter of 2025, alongside significant progress in its AVERSA Fentanyl development and a substantial preferred stock dividend.

Nutriband Inc. announced a narrower net loss and increased revenue for the quarter ended April 30, 2025, driven by growth in its contract manufacturing segment, despite continued cash burn and ongoing reliance on external financing for its AVERSA drug development pipeline.

Nutriband Inc. saw a revenue increase and a reduction in net losses for the quarter ended October 31, 2024, supported by recent equity financing.

Nutriband Inc. reported a widened net loss for the quarter ended July 31, 2024, despite a significant equity financing round.

Nutriband Inc. reported a net loss of $1.9 million for the first quarter of 2024, driven by a significant increase in research and development expenses related to its abuse-deterrent fentanyl transdermal system.